Literature DB >> 12589104

Successful combination therapy of cyclosporine and methotrexate for refractory polymyositis with anti-Jo-1 antibody: a case report.

Hyun Kyu Chang1, Deok Hee Lee.   

Abstract

Although corticosteroids have been the initial agent for the treatment of inflammatory myopathies (IM), immunosuppressive agents such as azathioprine, methotrexate, cyclophosphamide, or cyclosporine are commonly required to control the disease except mild cases. On the other hand, the efficacy of combination therapy of cyclosporine and methotrexate in severe rheumatoid arthritis has been proven without serious side effects. However, in treatment-resistant myositis, the experience of such a therapy is very limited, and has not been described in refractory polymyositis with anti-Jo-1 antibody. Here, we report a young female patient with recalcitrant polymyositis and anti-Jo-1 antibody who was successfully treated with the combination therapy of cyclosporine and methotrexate. At first, the myositis did not respond to several agents, such as corticosteroid, monthly pulse cyclophosphamide, azathioprine, or cyclosporine. Methotrexate was initially avoided as treatment regimen because of its potential pulmonary toxicity in the case with preexisting lung disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589104      PMCID: PMC3054986          DOI: 10.3346/jkms.2003.18.1.131

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  2 in total

1.  Rituximab in life threatening antisynthetase syndrome.

Authors:  E Vandenbroucke; J C Grutters; J Altenburg; W G Boersma; E J ter Borg; J M M van den Bosch
Journal:  Rheumatol Int       Date:  2009-02-01       Impact factor: 2.631

Review 2.  Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome.

Authors:  Magdalena Jankowska; Barbara Butto; Alicja Debska-Slizień; Bolesław Rutkowski
Journal:  Rheumatol Int       Date:  2007-01-13       Impact factor: 3.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.